Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by bigmack1on Sep 14, 2016 9:31pm
79 Views
Post# 25238639

RE:RE:Clinical Development

RE:RE:Clinical DevelopmentAgreed Jefferam, those are all sensible observations. I guess the fear is that it may take a while to get traction and momentum. Does anyone think that we could see a meaningful NR over the next month or two? I am new to this stock, but I like what I see in terms of the company (not the low volume), but the pipeline is fantastic. It would be nice if investors could come around and help inhabit this virtual ghost town. Its a great company with a very attractive pipeline. 
One other concern of mine is the next earnings report, is there an outside chance that we might see some revenue? I know Dan hinted at the possibility that things will be better moving forward but I would like to know what others think. Its very tempting to load more as it tanks, however, its scary as well. This is not a blue chip. :)

Bullboard Posts